Back to Search
RACHEL VILE, MD
MD
Critical Care Medicine (Internal Medicine) Physician
NPI: 1801841952IndividualAccepts Medicare
Specialties, Licenses & Credentials
Critical Care Medicine (Internal Medicine) PhysicianPrimary
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
D0058376(MD)
Education
KANSAS CITY COLLEGE OF MEDICINE AND SURGERY
Class of 1997
Research & Publications (20)
Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery.
PMID 18784747·Gene Ther·2009
4-observational
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.
PMID 19630549·Hum Gene Ther·2009
6-review
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
PMID 19509134·Clin Cancer Res·2009
7-preclinical
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.
PMID 19147761·Clin Cancer Res·2009
7-preclinical
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009.
PMID 19483767·Mol Ther·2009
8-other
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
PMID 19282847·Gene Ther·2009
7-preclinical
Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
PMID 18079753·Gene Ther·2008
7-preclinical
Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
PMID 18509378·Gene Ther·2008
8-other
Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.
PMID 18676766·Clin Cancer Res·2008
7-preclinical
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
PMID 18172278·Clin Cancer Res·2008
7-preclinical
Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.
PMID 18600182·J Immunother·2008
7-preclinical
Reovirus activates human dendritic cells to promote innate antitumor immunity.
PMID 18424722·J Immunol·2008
8-other
Exploiting synergies between radiation and oncolytic viruses.
PMID 18683101·Curr Opin Mol Ther·2008
6-review
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
PMID 18305577·Gene Ther·2008
7-preclinical
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
PMID 18323793·Gene Ther·2008
3-trial
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.
PMID 18057935·Cancer Immunol Immunother·2008
7-preclinical
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.
PMID 18431359·Mol Ther·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2401 RESEARCH BLVD, SUITE 350
ROCKVILLE, MD 20850 - Phone
- (301) 330-6982
Quick Facts
- NPI
- 1801841952
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile